TuHURA Biosciences, Inc./NV
HURA · XNASCIK 1498382fmd_1JQ9PQFZ5V9S5RYE6YK4RMXN7NManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Jun 30, 2026, 64 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | 0 | 0 | 0 |
| Research and development | (5) | (7) | 4 | 4 | 12 | 15 | 9 | – | 13 | 21 |
| Total operating expenses | (8) | (11) | 8 | (9) | 38 | 23 | 15 | – | 18 | 32 |
| Operating income | – | – | – | – | – | – | – | – | – | – |
| Interest expense | – | – | – | – | 0 | – | – | 0 | 4 | 1 |
| Other non-operating income (expense) | (0) | (0) | 0 | 0 | (0) | 0 | 0 | – | (4) | 2 |
| Income before taxes | – | – | – | – | – | – | – | 29 | (22) | (30) |
| Income tax expense | – | – | – | – | – | – | – | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | 29 | (22) | (30) |
| Net income | 8 | 11 | (8) | (9) | (38) | (23) | (15) | – | (22) | (30) |
| Net income to common shareholders | 9 | 11 | (8) | (9) | (42) | (25) | (15) | – | (23) | (30) |